Rosen Law Firm Investigates Impact Biomedical for Potential Securities Violations

Firm Encourages Investors to Inquire About Class Action Lawsuit

Apr. 12, 2026 at 11:39am

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a stack of legal documents, a gavel, and a magnifying glass arranged elegantly on a clean, white seamless background, conceptually representing the legal process of a securities class action lawsuit.A securities class action lawsuit could allow impacted Impact Biomedical investors to potentially recover losses through the legal system.NYC Today

The Rosen Law Firm, a global investor rights law firm, has announced an investigation into potential securities claims on behalf of shareholders of Impact Biomedical Inc. (NYSE American: IBO). The firm believes Impact Biomedical may have issued materially misleading business information to the investing public.

Why it matters

This investigation could lead to a class action lawsuit, which would allow impacted investors to potentially recover losses without paying out-of-pocket fees or costs. The Rosen Law Firm has a strong track record of success in securities class actions, having secured over $438 million for investors in 2019 alone.

The details

The Rosen Law Firm is preparing a class action lawsuit seeking to recover investor losses related to the alleged misleading information from Impact Biomedical. Investors who purchased Impact Biomedical securities may be eligible for compensation through the class action. The firm is encouraging investors to contact them to learn more about joining the prospective lawsuit.

  • The investigation was announced on April 12, 2026.

The players

Rosen Law Firm

A global investor rights law firm that specializes in securities class actions and shareholder derivative litigation. The firm has achieved some of the largest securities class action settlements and has been ranked as a top firm for securities class action settlements.

Impact Biomedical Inc.

A publicly traded biopharmaceutical company listed on the NYSE American exchange under the ticker symbol IBO.

Got photos? Submit your photos here. ›

What they’re saying

“If you purchased Impact Biomedical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.”

— Phillip Kim, Attorney

What’s next

Investors interested in joining the potential class action lawsuit are encouraged to contact the Rosen Law Firm through their website or by calling the firm directly.

The takeaway

This investigation highlights the importance for investors to be vigilant about potential securities violations by publicly traded companies. The Rosen Law Firm's track record suggests they have the expertise and resources to effectively represent impacted shareholders in a class action lawsuit against Impact Biomedical.